Immunocore Holdings plc (NASDAQ:IMCR - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for Immunocore in a research note issued on Monday, April 29th. Leerink Partnrs analyst J. Chang anticipates that the company will earn ($0.49) per share for the quarter. Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Immunocore's current full-year earnings is ($1.54) per share. Leerink Partnrs also issued estimates for Immunocore's Q2 2024 earnings at ($0.41) EPS, Q3 2024 earnings at ($0.44) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.58) EPS and FY2025 earnings at ($2.14) EPS.
Immunocore (NASDAQ:IMCR - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.12). The company had revenue of $70.16 million for the quarter, compared to analysts' expectations of $53.25 million. Immunocore had a negative return on equity of 15.78% and a negative net margin of 22.48%. The firm's quarterly revenue was up 22.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.63) EPS.
A number of other analysts have also recently weighed in on IMCR. Oppenheimer reissued an "outperform" rating and issued a $87.00 price objective (up previously from $85.00) on shares of Immunocore in a research report on Thursday, February 29th. Mizuho lifted their price target on Immunocore from $86.00 to $90.00 and gave the stock a "buy" rating in a research report on Tuesday, March 5th. Guggenheim reaffirmed a "buy" rating and set a $92.00 price target on shares of Immunocore in a research report on Tuesday, April 23rd. SVB Leerink began coverage on Immunocore in a research report on Monday. They set an "outperform" rating and a $74.00 price target for the company. Finally, Canaccord Genuity Group lifted their price target on Immunocore from $60.00 to $63.00 and gave the stock a "hold" rating in a research report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $80.92.
View Our Latest Analysis on Immunocore
Immunocore Stock Up 0.7 %
Shares of Immunocore stock traded up $0.41 during trading on Thursday, reaching $59.46. The company's stock had a trading volume of 396,828 shares, compared to its average volume of 480,633. The company has a quick ratio of 3.77, a current ratio of 3.80 and a debt-to-equity ratio of 0.13. The company has a market cap of $2.96 billion, a price-to-earnings ratio of -51.26 and a beta of 0.92. Immunocore has a 1-year low of $42.21 and a 1-year high of $76.98. The company has a 50-day simple moving average of $61.68 and a two-hundred day simple moving average of $60.94.
Institutional Investors Weigh In On Immunocore
Large investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Immunocore during the 3rd quarter worth approximately $650,000. TD Asset Management Inc boosted its holdings in shares of Immunocore by 109.9% during the 3rd quarter. TD Asset Management Inc now owns 301,920 shares of the company's stock worth $15,670,000 after purchasing an additional 158,086 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Immunocore by 54.9% during the 3rd quarter. Assetmark Inc. now owns 11,011 shares of the company's stock worth $571,000 after purchasing an additional 3,902 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in shares of Immunocore by 1.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 108,651 shares of the company's stock worth $5,639,000 after purchasing an additional 1,513 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in shares of Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company's stock worth $43,000 after purchasing an additional 426 shares during the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.
Immunocore Company Profile
(
Get Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
Further Reading
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
